Peptide Therapy in the UAE: How Treatment Actually Works

If you have been reading about peptide therapy in the UAE, you have probably found two kinds of page: sellers listing vials, and forums arguing about protocols. Neither answers the question most people actually have, which is how a person in Dubai or Abu Dhabi gets access to this properly, and how to tell whether they should.

This guide covers what separates verified material from a hopeful label, what the regulatory position in the UAE actually is, and what happens in a proper consultation.

Most peptide compounds are not approved medicines. That single fact drives everything else. It means there is no pharmacy counter to walk up to, which is why an unregulated market filled the gap, and why so much of the information online is written by people selling something.

It also means the important variable is not which website you order from. It is whether anyone has actually looked at you before you start. Two people with identical symptoms can need opposite answers, and no listing page can tell them apart.

Whatever route you take, the same two questions decide whether what you have been given is real.

Purity, by HPLC

High performance liquid chromatography separates everything in the sample and reports each fraction as a percentage. A genuine result is a number, 98.6 percent, not a "high purity" claim. Anything below roughly 98 percent is worth questioning.

Identity, by mass spectrometry

Mass spectrometry weighs the molecule and confirms it matches what the labelled peptide should weigh. Purity without identity tells you the vial is clean but not what is in it. You want both.

Batch-specific, not product-line

A Certificate of Analysis should cover the batch your vial came from, with its own lot number and test date. A generic CoA reused across a product line for years is a filing exercise. This is standard practice in pharmaceutical supply chains and it is a reasonable thing to expect anywhere else.

Independent testing

Third-party testing means a lab with no stake in the outcome did the work. Janoshik Analytical is the name that comes up most in this field, largely because its reports can be checked through its own portal rather than taken on trust. Ask to see the report for your batch; a clinic that cannot produce one is not verifying anything.

Cold chain, which the UAE makes non-negotiable

Peptides are supplied lyophilised because freeze-dried is their most stable state, but stability is not immunity. Ambient temperatures here are not kind to biological material, and a compound that spent two days in a warm vehicle can arrive with excellent paperwork and nothing much else. This is one of the clearest practical arguments for a route where the handling is somebody's professional responsibility.

The UAE regulates medicines tightly, and unapproved compounds are not something a member of the public can legitimately import and self-administer. Personal importation of regulated-medicine material carries real risk, and "it was sold as research material" is not a defence anyone should want to rely on.

Anything that is genuinely a regulated medicine reaches people through a licensed clinician rather than being bought online, and most of these compounds are not registered medicines at all, which is why the assessment, the documentation and the monitoring have to be put there deliberately. Our guide to the UAE regulatory position goes into this in more detail.

A Baseline consultation is AED 350, remote, and one to one, and the fee is credited against your program if you go ahead. In practice it covers:

• Your history and current medications, including anything that interacts badly with the compound classes involved.
• What you are actually trying to solve. A surprising amount of what sends people looking at peptides, fatigue, poor recovery, stalled body composition, has a more ordinary and more treatable explanation.
• Baseline bloods where they are needed, particularly for anything touching the growth-hormone axis or glucose handling.
• Whether treatment is appropriate at all. Sometimes it is not, and being told so plainly is part of what you are there for.
• If it is appropriate: the protocol, the monitoring schedule, and what to do if something feels wrong.

Each of these has its own reference page covering what it is, what the evidence shows, and who it suits:

• Retatrutide, GLP-1 / GIP / glucagon triple receptor agonist, investigational and still in Phase 3.
• Tesamorelin, a stabilised GHRH analogue studied in visceral adipose tissue and IGF-1 work.
• BPC-157 / TB-500, a dual tissue-repair pairing acting through complementary pathways.
• GHK-Cu, a copper peptide studied in wound healing, collagen synthesis and skin biology.
• MOTS-c, a mitochondrial-derived peptide studied in metabolic regulation and insulin sensitivity.
• NAD+, studied in cellular energy metabolism and longevity pathways.
• CJC-1295 / Ipamorelin, a GHRH analogue paired with a selective secretagogue.

The full set is on the treatments page.

The consultation is AED 350, credited against your program, and you can see who you will be speaking to before you book. If you would rather read first, the clinical guides cover each compound in depth.

This article is educational and is not a diagnosis, a treatment plan, or a recommendation to use any specific compound. A consultation decides what is appropriate for you.